The Polydeoxyribonucleotide (PDRN) cytotoxicity test is an essential in vitro biocompatibility evaluation for PDRN-based raw materials, injectables, wound-care products and cosmetic formulations, performed in accordance with ISO 10993-5 and related international standards. This article provides a comprehensive technical overview of the testing principle, sample preparation, assay methods, acceptance criteria and regulatory applications of PDRN cytotoxicity testing in accredited third-party laboratories. Understanding these requirements helps manufacturers ensure product safety, accelerate regulatory submission and support quality control throughout the product life cycle.
Technical Overview
Polydeoxyribonucleotide (PDRN) is a purified mixture of linear deoxyribonucleotide polymers, typically extracted from the sperm cells (milt) of salmon or trout through controlled depolymerization, with a broad molecular weight distribution commonly reported between 50 and 2000 kDa. PDRN acts primarily as an agonist of the adenosine A2A receptor and is widely used in regenerative medicine, wound healing, anti-ischemic therapy and aesthetic dermatology due to its documented effects on cell proliferation, angiogenesis and tissue repair.
Because PDRN-containing products frequently contact tissues, breached skin or the bloodstream, cytotoxicity testing represents the first and most fundamental step of the biological safety evaluation hierarchy defined by the ISO 10993 series. The PDRN cytotoxicity test evaluates whether the test article, or an extract prepared from it, causes cell death, growth inhibition or morphological damage in cultured mammalian cells under standardized in vitro conditions. The most widely applied standards include ISO 10993-5 (Tests for in vitro cytotoxicity), GB/T 16886.5 (the Chinese national adoption of ISO 10993-5), and ASTM F813 and ASTM F895 for direct-contact and agar-diffusion cytotoxicity methods, respectively.
The test is typically performed using mouse fibroblast cell lines such as L929, in which cells are exposed to graded concentrations of the PDRN sample or its extract, and cell viability is quantified using colorimetric endpoints such as the MTT, XTT, WST-8 or neutral red uptake assays. According to ISO 10993-5, a test article is considered non-cytotoxic when the mean cell viability of the treated group remains at or above 70% of the negative control, with no dose-dependent decline in viability across the tested dilution series.
Testing Samples
PDRN Raw Materials and Active Ingredients
Bulk PDRN sodium salt powders, sterile PDRN active pharmaceutical ingredients and depolymerized DNA fractions intended for downstream formulation are tested to verify that residual impurities from the extraction and purification process (such as proteins, organic solvents or endotoxin-associated contaminants) do not compromise in vitro cell viability.
PDRN Injectable Solutions and Lyophilized Preparations
Ready-to-use PDRN solutions in ampoules or vials, as well as lyophilized powders for reconstitution, are evaluated in their final dosage form. Because these products are administered parenterally or intradermally, they are tested neat (undiluted) and as serial dilutions in complete culture medium to construct a full concentration-response profile.
PDRN-Containing Medical Devices
Wound dressings, hydrogels, collagen matrices, bone-graft substitutes and tissue-engineering scaffolds incorporating PDRN are tested according to the extract-based protocols of ISO 10993-5 in combination with the sample preparation requirements of ISO 10993-12, using physiologically relevant extraction conditions.
Cosmetic and Dermal Products
Mesotherapy solutions, skin-boosters, serums and topical formulations containing PDRN or sodium DNA undergo cytotoxicity screening to support cosmetic safety assessments and to substantiate claims of skin compatibility, particularly for products applied on compromised or microneedled skin.
Testing Items
A typical PDRN cytotoxicity test package includes the following evaluation items, selected according to the physical form of the product and the applicable regulatory framework:
- Quantitative in vitro cytotoxicity using the MTT, XTT, WST-8 (CCK-8), resazurin (Alamar Blue) or neutral red uptake assay, expressed as percent cell viability relative to the negative control.
- Qualitative cytotoxicity assessment based on morphological observation under phase-contrast or optical microscopy, with reactivity graded from Grade 0 (no reactivity) to Grade 4 (severe reactivity).
- Extract dilution test (indirect contact method) for devices, dressings and solid or semi-solid PDRN matrices.
- Direct contact test for materials that interface directly with tissue, performed with and without an intermediate agar layer as appropriate.
- Dose-response cytotoxicity profiling of injectable PDRN solutions across serial dilutions, including the determination of the half-maximal inhibitory concentration (IC50) where scientifically justified.
- Parallel assessment of pH and osmolality of concentrated test solutions, since hyperosmolar or extreme-pH preparations may generate non-specific reductions in viability unrelated to genuine cytotoxicity.
Testing Methods
Sample Preparation and Extraction
Solid and semi-solid PDRN-containing materials are extracted in complete culture medium (Dulbecco's Modified Eagle Medium supplemented with serum) under aseptic conditions following ISO 10993-12. Standard extraction ratios include 0.2 g/mL for non-porous or elastomeric materials, 0.1 g/mL for porous or absorbable matrices, and surface-area ratios of 3 cm²/mL or 6 cm²/mL for membranes and dressings. Common extraction conditions are 37 ± 1 °C for 24 ± 2 hours, with extended 72-hour extraction or accelerated conditions (50 °C for 72 hours or 70 °C for 24 hours) applied when exaggerated exposure is required. Liquid PDRN preparations are tested directly after sterile filtration or as dilution series prepared in culture medium, typically covering 100%, 50%, 25%, 12.5% and lower volume fractions.
Test System and Cell Culture
The L929 mouse fibroblast cell line is the preferred and most widely accepted test system under ISO 10993-5, given its extensive historical database in medical device biocompatibility testing. Alternative systems such as V79 hamster lung fibroblasts, BALB/c 3T3 cells or human dermal fibroblasts may be used where justified by the intended clinical application. Cells are routinely cultured in complete medium at 37 °C in a humidified atmosphere of 5% carbon dioxide and are used in the logarithmic growth phase with verified viability above 90% before seeding.
MTT Assay Procedure
In the quantitative MTT assay, cells are seeded into 96-well microplates at approximately 1 × 10⁵ cells/mL and allowed to attach for approximately 24 hours. The culture medium is then replaced with the test extracts or PDRN dilutions, and plates are incubated for 24 ± 2 hours of exposure. Following exposure, MTT solution (approximately 1 mg/mL) is added for 2 to 4 hours, during which metabolically active cells convert the tetrazolium salt into insoluble formazan crystals. The crystals are solubilized in acidified isopropanol or DMSO, and absorbance is measured at 570 nm with a 650 nm reference wavelength. Percent viability is calculated as the corrected absorbance of the treated group divided by that of the negative control group multiplied by 100.
Controls and Acceptance Criteria
Each experiment includes a negative control (such as high-density polyethylene reference material or blank extraction medium) and a positive control (such as latex extract, sodium dodecyl sulfate or Triton X-100) to demonstrate assay sensitivity. The run is valid only when the positive control suppresses viability to a clearly cytotoxic level and the negative control maintains a healthy, confluent monolayer. Under ISO 10993-5, viability of 70% or greater indicates the sample is non-cytotoxic; values below 70% trigger evaluation of dose-response behavior, pH and osmolality effects, and, where necessary, confirmatory testing with an alternative endpoint.
Data Evaluation and Reporting
The final report documents sample description, extraction parameters, cell line and passage number, exposure conditions, individual and mean absorbance values, calculated viability percentages, qualitative morphology grades, control performance and a clear conclusion on cytotoxicity classification. Statistical analysis of replicate wells and across independent runs supports the reliability of the classification and is typically expected in regulatory submissions.
Applications
PDRN cytotoxicity testing serves multiple purposes across the product development and regulatory landscape:
- Regulatory biocompatibility files: the in vitro cytotoxicity report is a mandatory or strongly expected component of biological evaluation plans submitted to national medical device and pharmaceutical authorities under the ISO 10993-1 risk management framework.
- Batch release and quality control: manufacturers of PDRN injectables and wound-care products use cytotoxicity screening as part of routine lot verification to monitor process consistency and detect contamination events.
- Formulation and excipient screening: comparative cytotoxicity profiling supports the selection of buffers, preservatives, salts and carrier materials used in PDRN-based formulations.
- Supplier qualification: incoming PDRN raw materials from different sources or purification processes can be compared on a standardized in vitro safety basis.
- Cosmetic safety support: cytotoxicity data complement alternative-method results, such as reconstructed human epidermis models, in building a weight-of-evidence safety dossier for dermal and aesthetic applications.
- Research and development: academic and industrial laboratories apply the same test design to evaluate novel PDRN delivery systems, combination scaffolds and surface-immobilized PDRN coatings.
FAQ
Which standards govern the PDRN cytotoxicity test?
The core standard is ISO 10993-5 (Tests for in vitro cytotoxicity), supported by ISO 10993-12 for sample preparation and extraction. In China, the equivalent national standard is GB/T 16886.5, and additional method guidance can be drawn from ASTM F813 and ASTM F895. Pharmacopeial in vitro cytotoxicity chapters may also be applicable for PDRN products regulated as pharmaceuticals.
What is the pass criterion for the test?
According to ISO 10993-5, a sample is considered non-cytotoxic when the mean viability of treated cells is 70% or higher relative to the negative control. In qualitative tests, reactivity of Grade 2 (mild) or below is generally interpreted as acceptable, subject to the biological evaluation plan.
Why is the L929 cell line preferred?
L929 mouse fibroblasts are explicitly recommended by ISO 10993-5 and offer decades of validated historical use in biocompatibility testing, which facilitates result comparison and regulatory acceptance. Other characterized lines may be substituted with scientific justification.
How are injectable PDRN solutions tested differently from solid materials?
Injectables are evaluated directly as neat samples and as serial dilutions in culture medium rather than as extracts, allowing a full concentration-response assessment. Because concentrated PDRN solutions can be hyperosmolar, osmolality and pH are measured in parallel to distinguish genuine cytotoxicity from non-specific physicochemical effects.
How much sample is required and what is the typical turnaround time?
Common sample requirements are at least 4 grams of solid material or 10 milliliters of liquid preparation per test, with additional quantities retained for confirmation testing. The complete workflow, including extraction, cell culture, exposure, viability measurement and report issuance, generally requires two to four weeks.
Can the cytotoxicity test replace the full biocompatibility evaluation?
No. Cytotoxicity is one component of the overall biological evaluation defined by ISO 10993-1. Depending on the nature and duration of tissue contact, additional endpoints such as sensitization, irritation, intracutaneous reactivity, genotoxicity and systemic toxicity may also be required by the responsible regulatory authority.
What factors can cause false-positive results?
High osmolality, non-physiological pH, residual depolymerization reagents, endotoxin contamination and excessive viscosity can all reduce measured viability without reflecting true material cytotoxicity. Dilution-based re-testing, dialysis of the extract or complementary analytical screening is used to investigate and resolve such findings.